Johnson Kimberly J, Barnes Justin M, Delavar Arash, O'Connell Caitlin P, Wang Xiaoyan
Brown School, Washington University in St. Louis, Campus Box 1196, One Brookings Drive, St. Louis, MO, 63130, USA.
Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA.
J Neurooncol. 2023 Jan;161(1):117-126. doi: 10.1007/s11060-022-04227-w. Epub 2023 Jan 7.
Prior research indicates that the volume of central nervous system (CNS) tumor patients seen by a facility is associated with outcomes. However, most studies have focused on short-term survival and specific CNS tumor subtypes. Our objective was to examine whether facility CNS tumor patient volume is associated with longer-term CNS tumor survival overall and by subtype.
We obtained National Cancer Database (NCDB) data including individuals diagnosed with CNS tumors from 2004 to 2016. Analyses were stratified by age group (0-14, 15-39, 40-64, and ≥ 65 years) and tumor type. We used Cox Proportional Hazards (PH) regression and restricted mean survival time (RMST) analyses to examine associations between survival and facility patient volume percentile category adjusting for potential confounding factors.
Our analytic dataset included data from 130,830 individuals diagnosed with malignant first primary CNS tumors. We found a consistently reduced hazard rate of death across age groups for individuals reported by higher vs. lower (> 95th vs. ≤ 70th percentile) volume facilities (hazard ratio (HR) = 0.78, 95% confidence interval (CI) 0.64-0.95; HR = 0.87, 95% CI 0.78-0.96; HR = 0.82, 95% CI 0.76-0.88; HR = 0.80, 95% CI 0.75-0.86). Significantly longer survival times within 5 years for higher vs. lower volume facilities were observed ranging from 1.20 months (15-39) to 3.08 months (40-64) higher. Associations varied by CNS tumor subtype for all age groups.
These results suggest facility factors influence CNS tumor survival with longer survival for patients reported by higher volume facilities. Understanding these factors will be critical to developing strategies that eliminate modifiable differences in survival times.
先前的研究表明,医疗机构诊治的中枢神经系统(CNS)肿瘤患者数量与治疗结果相关。然而,大多数研究集中在短期生存和特定的CNS肿瘤亚型上。我们的目标是研究医疗机构的CNS肿瘤患者数量是否与长期的CNS肿瘤总体生存率以及按亚型划分的生存率相关。
我们获取了国家癌症数据库(NCDB)的数据,其中包括2004年至2016年被诊断为CNS肿瘤的个体。分析按年龄组(0 - 14岁、15 - 39岁、40 - 64岁和≥65岁)和肿瘤类型进行分层。我们使用Cox比例风险(PH)回归和受限平均生存时间(RMST)分析,以检验生存率与医疗机构患者数量百分位类别之间的关联,并对潜在的混杂因素进行调整。
我们的分析数据集包括130,830例被诊断为原发性恶性CNS肿瘤患者的数据。我们发现,与患者数量较低(>第95百分位与≤第70百分位)的医疗机构报告的患者相比,各年龄组中患者数量较高的医疗机构报告的患者死亡风险率持续降低(风险比(HR)= 0.78,95%置信区间(CI)0.64 - 0.95;HR = 0.87,95% CI 0.78 - 0.96;HR = 0.82,95% CI 0.76 - 0.88;HR = 0.80,95% CI 0.75 - 0.86)。观察到患者数量较高的医疗机构与患者数量较低的医疗机构相比,5年内的生存时间显著更长,长1.20个月(15 - 39岁)至3.08个月(40 - 64岁)。所有年龄组中,关联因CNS肿瘤亚型而异。
这些结果表明,医疗机构因素会影响CNS肿瘤的生存情况,患者数量较多的医疗机构报告的患者生存期更长。了解这些因素对于制定消除生存时间中可改变差异的策略至关重要。